Key Takeaways
- Puma Biotechnology granted 31,625 inducement restricted stock units to five new non-executive employees.
- Stock awards vest over three years, encouraging long-term commitment from new hires.
- Puma focuses on developing innovative cancer treatments, including the FDA-approved NERLYNX® and the new alisertib drug.
Puma Biotechnology Grants Stock Awards
Puma Biotechnology, Inc. announced the approval of inducement restricted stock unit awards totaling 31,625 shares of common stock to five new non-executive employees. This decision was made by the company’s Board of Directors’ Compensation Committee on April 1, 2026. The awards fall under Puma’s 2017 Employment Inducement Incentive Award Plan, aimed at attracting new talent through equity awards.
The vesting schedule for these stock units spans three years. One-third of the shares will vest on the first anniversary of the award’s commencement date (April 1, 2026), while the remaining shares will vest at a rate of one-sixth every six months thereafter, contingent upon continued employment. This incentive aligns with Nasdaq Listing Rule 5635(c)(4), which facilitates grants as inducements to new employees.
Founded with a mission to advance cancer care, Puma Biotechnology focuses on developing and commercializing groundbreaking therapeutic products. The company, established in 2011, in-licensed the rights to PB272 (neratinib), which was approved by the U.S. Food and Drug Administration in 2017 for treating early-stage HER2-overexpressed breast cancer following trastuzumab therapy. Marketed under the brand name NERLYNX®, this oral treatment has gained further FDA approvals in recent years for advanced HER2-positive breast cancer, as well as marketing authorization in Europe.
In September 2022, Puma struck an exclusive licensing agreement for alisertib, an orally-administered inhibitor targeting aurora kinase A. The initial focus will be on treating small cell lung cancer and breast cancer. By February 2024, the company launched the ALISCA™-Lung1 Phase II clinical trial for alisertib monotherapy aimed at extensive-stage small cell lung cancer patients. Another trial, ALISCA™-Breast1, initiated in November 2024, is exploring alisertib combined with endocrine therapy for HER2-negative, HR-positive metastatic breast cancer.
Puma Biotechnology is committed to advancing treatment options in oncology, demonstrating its growth and innovation within the biopharmaceutical sector.
The content above is a summary. For more details, see the source article.